SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Silverback Therapeutics, Inc. (Nasdaq – SBTX)
BALA CYNWYD – July 26, 2022 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Silverback, Inc. (“Silverback” or the “Company”) (Nasdaq – SBTX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company’s agreement to be acquired by ARS Pharmaceuticals, Inc. (“ARS”). Under the terms of the merger agreement, assuming that Silverback’s net cash at closing is $240 million, Silverback equity holders are expected to own approximately 37% of the combined company and pre-merger ARS equity holders are expected to own approximately 63% of the combined company on a fully-diluted basis on a treasury stock method.
The investigation concerns whether the Silverback Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether ARS is paying too little for the Company.
If you own shares of Silverback stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 855-576-4847.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.